| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2018 | PCRX Pacira Biosciences, Inc. | Hastings Paul J75 | Director | Sell | 771 | $33.90 | $26,136.90 | -21.9% | |
| Jun 1, 2018 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 12,350 | $97.34 | $1,202,163.82 | -42.5% | |
| Jun 1, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $47.34 | $47,340.00 | -100% | |
| Jun 1, 2018 | BCRX Biocryst Pharmaceuticals Inc | Sheridan William P67 | Senior VP - CMO | Sell | 42,112 | $6.30 | $265,305.60 | -66.7% | |
| Jun 1, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 39,522 | $85.31 | $3,371,661.34 | - | |
| Jun 1, 2018 | CANN Trees Corp (colorado) | Boockvar Peter | Director | Sell | 32,000 | $3.44 | $110,178.68 | -56.3% | |
| Jun 1, 2018 | COLL Collegium Pharmaceutical, Inc | Ciaffoni Joseph | Chief Operating Officer | Sell | 79,683 | $22.59 | $1,799,712.87 | -20.3% | |
| May 31, 2018 | LLY Eli Lilly & Co | Conterno Enrique A87 | SVP&Pres, Lillydiab &Lillyusa | Sell | 25,000 | $85.00 | $2,125,000.00 | -16.7% | |
| May 31, 2018 | CANN Trees Corp (colorado) | Whitson Shelly | Chief Administrative Officer | Buy | 38,051 | $0.75 | $28,538.25 | New | |
| May 30, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 180,000 | $83.85 | $15,092,640.00 | -0.1% | |
| May 30, 2018 | CANN Trees Corp (colorado) | Boockvar Peter | Director | Sell | 18,000 | $3.57 | $64,175.70 | -20.8% | |
| May 29, 2018 | LLY Eli Lilly & Co | Shaw Christi | SVP And Pres., Lilly Bio-meds | Sell | 8,426 | $82.10 | $691,774.60 | -100% | |
| May 29, 2018 | KNSA Kiniksa Pharmaceuticals International, Plc | Cormorant Asset Management, LP49 | 10% Owner | Buy | 69,444 | $18.00 | $1,249,992.00 | +8.4% | |
| May 29, 2018 | KNSA Kiniksa Pharmaceuticals International, Plc | Flynn James E62 | 10% Owner, *possible Member Of 10% Group | Buy | 843,352 | $18.97 | $15,996,834.49 | +55.3% | |
| May 29, 2018 | KNSA Kiniksa Pharmaceuticals International, Plc | Baker Bros. Advisors LP59 | Director, 10% Owner | Buy | 3,000,000 | $18.00 | $54,000,000.00 | New | |
| May 25, 2018 | TLPH Talphera, Inc. | Asadorian Raffi | Chief Financial Officer | Buy | 5,000 | $3.18 | $15,922.50 | +22.7% | |
| May 25, 2018 | SNY Sanofi | Sanofi | 10% Owner | Buy | 150,000 | $49.00 | $7,350,000.00 | +3.7% | |
| May 24, 2018 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 1,377 | $51.15 | $70,433.55 | -5.6% | |
| May 24, 2018 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 20,000 | $45.22 | $904,424.00 | -10.4% | |
| May 24, 2018 | AVDL Avadel Pharmaceuticals Plc | Anderson Michael S | Chief Executive Officer | Buy | 3,000 | $6.44 | $19,320.00 | +1.2% | |
| May 22, 2018 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 20,000 | $45.46 | $909,163.44 | -1.5% | |
| May 21, 2018 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 130,000 | $40.11 | $5,213,770.00 | +2.3% | |
| May 18, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 9,930 | $45.05 | $447,346.50 | -82.8% | |
| May 18, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 9,930 | $45.05 | $447,346.50 | -82.8% | |
| May 17, 2018 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 20,000 | $46.14 | $922,846.04 | -5.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.